---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-26-002725"
form_type: "8-K"
ticker: "NVAX"
cik: "0001000694"
company_name: "NOVAVAX INC"
filed_at: "2026-01-12T23:59:59+00:00"
generated_at: "2026-05-16T10:45:27.169291+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.35
calibrated_materiality_score: 0.35
confidence: "low"
source: SEC EDGAR
---

# Novavax presents strategic update at J.P. Morgan; 2025 results pending

## Summary
- Preliminary financial results for year ended Dec 31, 2025 are being finalized and subject to change.
- No specific financial metrics disclosed; presentation focuses on strategic and business updates.
- Investor presentation delivered at 44th Annual J.P. Morgan Healthcare Conference on January 12, 2026.
- Company cautions that actual results may differ materially from preliminary data.

## SEC filing metadata
- accession: 0001104659-26-002725
- form_type: 8-K
- ticker: NVAX
- cik: 0001000694
- company_name: NOVAVAX INC
- filed_at: 2026-01-12T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.35
- calibrated_materiality_score: 0.35
- confidence: low
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1000694/000110465926002725/0001104659-26-002725-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1000694/000110465926002725/tm262897d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-26-002725
- JSON: https://secwatch.observer/filing/0001104659-26-002725.json
- Plain text: https://secwatch.observer/filing/0001104659-26-002725.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.